BU
ANIK icon

BBVA USA’s Anika Therapeutics ANIK Stock Holding History

BBVA USA’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$152K Sell
3,563
-3,440
-49% -$142K 0.01% 482
2021
Q2 		$303K Buy
+7,003
New +$298K 0.02% 415

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $418M AUM 3.34% 1-Year Est. Return

BBVA USA's ANIK Position: Q3 2021 in Review

BBVA USA reduced its Anika Therapeutics (ANIK) stake by 49% in Q3 2021, selling an estimated $142K and leaving 3,563 shares worth $152K. The position accounts for 0.01% of the portfolio, ranked #482.

BBVA USA first reported a position in ANIK in Q2 2021 and has held it in 2 quarters since. The position peaked at $303K in Q2 2021. 131 funds tracked by Wall St. Rank hold ANIK as of Q3 2021.

  • BBVA USA held 3,563 shares of Anika Therapeutics worth $152K as of Q3 2021.
  • BBVA USA sold 3,440 Anika Therapeutics shares in Q3 2021, an estimated $142K.
  • Anika Therapeutics made up 0.01% of BBVA USA's portfolio in Q3 2021, its #482 holding.
  • BBVA USA first reported a position in Anika Therapeutics in Q2 2021 and has held it in 2 quarters since.
  • BBVA USA's Anika Therapeutics position peaked at $303K in Q2 2021.
  • 131 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2021.

Based on BBVA USA's 13F filing for Q3 2021, filed 4 Nov 2021.